Apyx Medical Dirección

Dirección controles de criterios 2/4

El CEO de Apyx Medical es Charlie Goodwin , nombrado en Dec 2017, tiene una permanencia de 6.92 años. compensación anual total es $1.26M, compuesta por 38.2% salario y 61.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.24% de las acciones de la empresa, por valor de €123.91K. La antigüedad media del equipo directivo y de la junta directiva es de 0.9 años y 5.3 años, respectivamente.

Información clave

Charlie Goodwin

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO	38.2%
Permanencia del CEO	6.9yrs
Participación del CEO	0.2%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Charlie Goodwin en comparación con los beneficios de Apyx Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$1m	US$483k	-US$19m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$2m	US$483k	-US$23m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$2m	US$450k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$2m	US$450k	-US$12m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$2m	US$450k	-US$20m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$400k	-US$11m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$12m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$2m	US$15k	-US$14m

Compensación vs. Mercado: La compensación total de Charlie($USD1.26M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD472.15K).

Compensación vs. Ingresos: La compensación de Charlie ha sido consistente con los resultados de la empresa en el último año.

CEO

Charlie Goodwin (58 yo)

6.9yrs

Permanencia

US$1,261,470

Compensación

Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Charles Goodwin	President	6.9yrs	US$1.26m	0.24% € 123.9k
Matthew Hill	CFO, Treasurer & Secretary	less than a year	US$445.95k	0.021% € 10.8k
Moshe Citronowicz	Senior Vice President	12.8yrs	US$538.31k	1.21% € 628.5k
Stavros Vizirgianakis	Executive Chairman	less than a year	sin datos	4.64% € 2.4m
Shawn Roman	Chief Operating Officer	no data	sin datos	sin datos

0.9yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BOV no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Charles Goodwin	President	6.9yrs	US$1.26m	0.24% € 123.9k
Stavros Vizirgianakis	Executive Chairman	less than a year	sin datos	4.64% € 2.4m
Lawrence Waldman	Lead Independent Director	13.7yrs	US$162.56k	0.11% € 59.1k
Brian Kinney	Member of Medical Advisory Board	5.3yrs	sin datos	sin datos
Gregory Konesky	Member of Scientific Advisory Board	no data	US$9.30k	sin datos
Yuval Carmel	Member of Scientific Advisory Board	no data	sin datos	sin datos
Minnie Baylor-Henry	Independent Director	5.3yrs	US$116.56k	0% € 0
Dennis Chi	Member of Medical Advisory Board	7.8yrs	sin datos	sin datos
Diane Duncan	Member of Medical Advisory Board	6.5yrs	sin datos	sin datos
Paul Ruff	Member of Medical Advisory Board	5.3yrs	sin datos	sin datos
Richard Gentile	Member of Medical Advisory Board	5.3yrs	sin datos	sin datos
Edward Zimmerman	Member of Medical Advisory Board	5.3yrs	sin datos	sin datos

5.3yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de BOV se considera experimentada (5.3 años de antigüedad promedio).

Apyx Medical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

President recently bought €72k worth of stock

Apyx Medical Corporation, Annual General Meeting, Aug 10, 2023

Recent updates

Now 21% undervalued after recent price drop

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.13 loss in 3Q 2023)

Apyx Medical Corporation has filed a Follow-on Equity Offering in the amount of $7 million.

Apyx Medical Corporation has filed a Follow-on Equity Offering in the amount of $7 million.

Apyx Medical Corporation to Report Q3, 2024 Results on Nov 08, 2024

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.19 loss per share (vs US$0.029 loss in 2Q 2023)

Apyx Medical Corporation Revises Earnings Guidance for the Full Year Ended December 31, 2024

Apyx Medical Corporation to Report Q2, 2024 Results on Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Now 37% overvalued

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.10 loss in 1Q 2023)

Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024

New major risk - Revenue and earnings growth

Apyx Medical Corporation to Report Q1, 2024 Results on May 09, 2024

Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024

Full year 2023 earnings released: US$0.54 loss per share (vs US$0.67 loss in FY 2022)

Apyx Medical Corporation to Report Q4, 2023 Results on Mar 21, 2024

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

New major risk - Revenue and earnings growth

Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

President recently bought €72k worth of stock

Apyx Medical Corporation Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.17 loss in 3Q 2022)

New minor risk - Market cap size

Apyx Medical Corporation to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

Apyx Medical Corporation Reaffirms Financial Guidance for the Year Ending December 31, 2023

Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.16 loss in 2Q 2022)

Apyx Medical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Apyx Medical Corporation, Annual General Meeting, Aug 10, 2023

Apyx Medical Corporation Announces FDA 510(k) Clearance for the Renuvion® Micro Handpiece

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.17 loss in 1Q 2022)

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2023

Full year 2022 earnings released: US$0.67 loss per share (vs US$0.44 loss in FY 2021)

Apyx Medical Corporation to Report Q4, 2022 Results on Mar 16, 2023

Apyx Medical Corporation Announces FDA 510(K) Submission for the Use of the Renuvion® Apr. Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction

Apyx Medical Corporation Launches New 'Apyx One Console' for Cosmetic Surgical Procedures in the United States

Apyx Medical Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 3Q 2021)

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2022

Apyx Medical Corporation to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

President recently bought €70k worth of stock

Second quarter 2022 earnings released

Apyx Medical Corporation Updates Earnings Guidance for the Full Year Ending December 31, 2022

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation

Apyx Medical Corporation Announces Results of the U.S. Ide Clinical Study Evaluating the Use of Renuvion to Improve the Appearance of Lax Skin in the Neck and Submental Region

Apyx Medical Corporation to Report Q2, 2022 Results on Aug 11, 2022

Apyx Medical Corporation Announces Receipt of 510(K) Clearance from FDA for Use of the Renuvion Dermal Handpiece for Specific Dermatological Procedures for Treatment of Moderate to Severe Wrinkles and Rhytides, Limited to Patients with Fitzpatrick Skin Types I, II or III

Apyx Medical Corporation(NasdaqGS:APYX) dropped from Russell 3000E Growth Index

Apyx Medical Corporation, Annual General Meeting, Aug 11, 2022

William E. Hattaway, Files A Complaint Against Apyx Medical Corporation

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Apyx Medical Corporation

Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® Cosmetic Technology in Dermal Resurfacing Procedures

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.14 loss in 1Q 2021)

Apyx Medical Corporation Updates Financial Guidance for the Year Ending December 31, 2022

Apyx Medical Corporation Announces FDA 510(K) Submission with Clinical Study Support for the Use of the Renuvion® APR Handpiece for Aesthetic Procedures to Improve Appearance of Lax Skin

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 49% undervalued after recent price drop

Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study Evaluating the Renuvion® Dermal Handpiece Using Apyx’s Helium Plasma Technology for Dermal Resurfacing Procedures

Apyx Medical Corporation to Report Q4, 2021 Results on Mar 17, 2022

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)